866-997-4948(US-Canada Toll Free)

Thyroid Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Cancer

No. of Pages : 117 Pages


Global Markets Directs, \'Thyroid Cancer Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Thyroid Cancer.
  • A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Thyroid Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Thyroid Cancer - Overview 10
Pipeline Products for Thyroid Cancer - Comparative Analysis 11
Thyroid Cancer - Therapeutics under Development by Companies 12
Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 14
Thyroid Cancer - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Thyroid Cancer - Products under Development by Companies 18
Thyroid Cancer - Products under Investigation by Universities/Institutes 19
Thyroid Cancer - Companies Involved in Therapeutics Development 20
AstraZeneca PLC 20
GlaxoSmithKline plc 21
Takeda Pharmaceutical Company Limited 22
Bio-Path Holdings, Inc. 23
Eisai Co., Ltd. 24
Bayer AG 25
Bionomics Limited 26
Azaya Therapeutics Incorporated 27
Vascular Biogenics Ltd. 28
Biovista Inc. 29
Trophogen, Inc. 30
centrose llc 31
Ecrins Therapeutics SAS 32
Thyroid Cancer - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 39
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Assessment by Therapeutic Class 47
Drug Profiles 50
sorafenib tosylate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
lenvatinib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
motesanib diphosphate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
selumetinib sulfate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VB-111 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
dabrafenib + trametinib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
dabrafenib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
pazopanib hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
docetaxel liposomal - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GSK-2256098 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Therapeutic p53 Gene Agent - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
BP-100-1.02 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
TRX-201 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ETD-5 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Vascular Endothelial Growth Factor Superagonist - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Thyroid Stimulating Hormone Analog - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Drug Adaptation Program - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
EDC-1 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
BVA-501 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
BVA-701 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Drug For Lung and Thyroid Cancer - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Drugs For Thyroid Cancer - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Thyroid Cancer - Recent Pipeline Updates 88
Thyroid Cancer - Dormant Projects 106
Thyroid Cancer - Discontinued Products 107
Thyroid Cancer - Product Development Milestones 108
Featured News & Press Releases 108
Nov 22, 2013: Nexavar Receives Approval for the Treatment of Differentiated Thyroid Cancer in the U.S. 108
Sep 30, 2013: Bayer Submits Nexavar for Marketing Authorization in Thyroid Cancer in Japan 109
Sep 12, 2013: Bayer to Present Data on Nexavar at the European Cancer Congress 2013 110
Aug 27, 2013: Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar Supplemental New Drug Application for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer 110
Jun 30, 2013: Bayer and Onyx Pharmaceuticals Announce Submission of FDA and EMA Applications for Nexavar for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer 111
Jun 03, 2013: EpiCept Announces Presentation Of New Crolibulin Data At ASCO 2013 112
Jun 02, 2013: Bayer Announces Sorafenib Phase III Data Shows Significant Improvement In Progression-Free Survival Time In Patients With Radioactive Iodine Refractory Differentiated Thyroid Cancer 113
May 16, 2013: VBL Therapeutics Announces Publication Of Phase I Data Of VB-111 In Journal Of Clinical Cancer Research 114
May 15, 2013: Onyx Pharma To Present Data On Nexavar At 49th American Society Of Clinical Oncology Annual Meeting 115
Feb 14, 2013: Eisai\'s Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 115

Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 117
Disclaimer 117

List of Table


Number of Products under Development for Thyroid Cancer, H2 2013 10
Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Thyroid Cancer - Pipeline by AstraZeneca PLC, H2 2013 20
Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H2 2013 21
Thyroid Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2013 22
Thyroid Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2013 23
Thyroid Cancer - Pipeline by Eisai Co., Ltd., H2 2013 24
Thyroid Cancer - Pipeline by Bayer AG, H2 2013 25
Thyroid Cancer - Pipeline by Bionomics Limited, H2 2013 26
Thyroid Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2013 27
Thyroid Cancer - Pipeline by Vascular Biogenics Ltd., H2 2013 28
Thyroid Cancer - Pipeline by Biovista Inc., H2 2013 29
Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2013 30
Thyroid Cancer - Pipeline by centrose llc, H2 2013 31
Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2013 32
Assessment by Monotherapy Products, H2 2013 33
Assessment by Combination Products, H2 2013 34
Number of Products by Stage and Target, H2 2013 37
Number of Products by Stage and Mechanism of Action, H2 2013 41
Number of Products by Stage and Route of Administration, H2 2013 44
Number of Products by Stage and Molecule Type, H2 2013 46
Number of Products by Stage and Therapeutic Class, H2 2013 49
Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2013 88
Thyroid Cancer - Dormant Projects, H2 2013 106
Thyroid Cancer - Discontinued Products, H2 2013 107

List of Chart


Number of Products under Development for Thyroid Cancer, H2 2013 10
Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 33
Number of Products by Top 10 Target, H2 2013 35
Number of Products by Stage and Top 10 Target, H2 2013 36
Number of Products by Top 10 Mechanism of Action, H2 2013 39
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 40
Number of Products by Top 10 Route of Administration, H2 2013 43
Number of Products by Stage and Top 10 Route of Administration, H2 2013 44
Number of Products by Top 10 Molecule Type, H2 2013 45
Number of Products by Stage and Top 10 Molecule Type, H2 2013 46
Number of Products by Top 10 Therapeutic Class, H2 2013 47
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *